The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of multipurpose prevention technologies in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women. (Visit www.avac.org/hvad for vaccine and broadly neutralizing antibody pipelines.)

### DELIVERY SYSTEM
- Oral pills
- Vaginal gel
- Vaginal ring
- Vaginal film
- Transdermal patch
- Enema
- Vaginal insert
- Rectal insert
- Intrauterine device
- Rectal gel
- Long-acting injectable
- Micro-array patch
- Subcutaneous injection
- Diaphragm
- Implant

### ACTIVE DRUG
- **AZ**: Acyclovir, Zovirax
- **MVA**: Maravirin
- **bNABs**: Broadly neutralizing antibody
- **GSK**: Cabotegravir
- **744**: GSK 744
- **MK**: MK-2048, MK-8591
- **DAP**: Dapivirine
- **Mab**: Monoclonal antibody
- **DAR**: Darunavir
- **1005**: PC-1005
- **PR**: Pringestin
- **DOL**: Dolutegravir
- **SPL7013**: SPL7013-VivaGel
- **TVF**: Tenofovir
- **TAF**: Tenofovir Atenoside
- **Ee**: Ethinylestradiol
- **Ett**: Tenofovir alafenamide/empircitabine
- **GRF**: Griffithsin
- **IOQ**: IOP-028
- **TDF**: Tenofovir disoproxil fumarate/empircitabine
- **Levo**: Levonorgestrel
- **SPI2**: SPI2-RANTES

*This formulation is for a 3-month vaginal ring*

**The components of this dual pill are approved but the drug combination is not, hence, it does not follow the traditional phase 1-3 R&D pathway.